Rossari Biotech Limited — PPTs, 18-01-2026: Investor Presentation

Rossari Biotech delivered a strong Q3 FY26, with consolidated revenue rising 13% YoY to Rs 581.7 Cr. For the nine months, revenue grew 14% YoY to Rs 1,711.5 Cr. While profitability was impacted by strategic investments, Q3 PAT was up 3% YoY to Rs 32.8 Cr, and 9M PAT increased 1.3% to Rs 103.2 Cr. Key segments like Animal Health & Nutrition (AHN) surged 39% YoY, Textile Specialty Chemicals (TSC) grew 18%, and Home, Personal Care & Performance Chemicals (HPPC) saw 11% growth, supported by strong exports.

Strategically, Rossari is doubling down on sustainable chemical solutions and expanding globally. A major development includes Board approval to establish new specialty chemical manufacturing facilities in Saudi Arabia through a wholly-owned subsidiary. This move is set to enhance supply capabilities and accelerate market reach. Management remains confident, expecting improved margins from operating leverage and product mix, focusing on disciplined execution and innovation for sustained profitable growth.